Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules

Pharmaceutical Research

Volumn 23, Issue 6, 2006, Pages 1243-1250

  Peltier, Sandra ^a,b   Oger, Jean Michel ^a,b   Lagarce, Frédéric ^a,b   Couet, William ^c   Benoît, Jean Pierre ^a,b  

^a U646   (France)

^b UNIVERSITÉ D'ANGERS   (France)

^c Lab de Pharm Galenique Biopharm   (France)

Author keywords

Nanocapsule; Oral bioavailability; P glycoprotein inhibitor; Paclitaxel; Pharmacokinetics

Indexed keywords

CAPTEX 8000; CREMOPHOR; DOCETAXEL; LIPOID S100 3; MACROGOL STEARATE; NANOCAPSULE; PACLITAXEL; PHOSPHATIDYLCHOLINE; SOLUTOL HS 15; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG HALF LIFE; DRUG STORAGE; FREEZE DRYING; MALE; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; DRUG COMPOUNDING; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; LIPIDS; LIPOSOMES; MALE; NANOSTRUCTURES; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33745386420     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-0022-2     Document Type: Article

References (38)

1. E. K. Rowinsky 1993 Clinical pharmacology of Taxol J. Natl. Cancer Inst. Monogr. 15 25 37
2. E. K. Rowinsky R. C. Donehower 1995 Paclitaxel (taxol) N. Engl. J. Med. 332 1004 1014
3. K. C. Nicolaou W. M. Dai R. K. Guy 1994 Chemistry and biology of taxol Angew. Chem. Int. Ed. Engl. 33 15 44
4. A. K. Singla A. Garg D. Aggarwal 2002 Paclitaxel and its formulations Int. J. Pharm. 235 179 192
5. L. van Zuylen J. Verweij A. Sparreboom 2001 Role of formulation vehicles in taxane pharmacology Invest. New Drugs 19 125 141
6. S. A. Wissing O. Kayser R. H. Muller 2004 Solid lipid nanoparticles for parenteral drug delivery Adv. Drug Deliv. Rev. 56 1257 1272
7. D. Le Garrec S. Gori L. Luo D. Lessard D. C. Smith M. A. Yessine M. Ranger J. C. Leroux 2004 Poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation J. Control. Release 99 83 101
8. T. K. Yeh Z. Lu M. G. Wientjes J. L. Au 2005 Formulating paclitaxel in nanoparticles alters its disposition Pharm. Res. 22 867 874
9. L. Mu S. S. Feng 2003 A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS J. Control. Release 86 33 48
10. P. Gao B. D. Rush W. P. Pfund T. Huang J. M. Bauer W. Morozowich M. S. Kuo M. J. Hageman 2003 Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability J. Pharm. Sci. 92 2386 2398
11. M. M. Malingre J. H. Beijnen J. H. Schellens 2001 Oral delivery of taxanes Invest. New Drugs 19 155 162
12. J. van Asperen O. van Tellingen M. A. van der Valk M. Rozenhart J. H. Beijnen 1998 Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A Clin. Cancer Res. 4 2293 2297
13. H. A. Bardelmeijer J. H. Beijnen K. R. Brouwer H. Rosing W. J. Nooijen J. H. Schellens O. van Tellingen 2000 Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein Clin. Cancer Res. 6 4416 4421
14. J. S. Woo C. H. Lee C. K. Shim S. J. Hwang 2003 Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031 Pharm. Res. 20 24 30
15. M. Ramaswamy X. Zhang H. M. Burt K. M. Wasan 1997 Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers J. Pharm. Sci. 86 460 464
16. A. Sparreboom J. van Asperen U. Mayer A. H. Schinkel J. W. Smit D. K. Meijer P. Borst W. J. Nooijen J. H. Beijnen O. van Tellingen 1997 Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine Proc. Natl. Acad. Sci. USA 94 2031 2035
17. C. M. Kruijtzer J. H. Beijnen J. H. Schellens 2002 Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview Oncologist 7 516 530
18. J. van Asperen O. van Tellingen A. Sparreboom A. H. Schinkel P. Borst W. J. Nooijen J. H. Beijnen 1997 Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833 Br. J. Cancer 76 1181 1183
19. S. Yang R. N. Gursoy G. Lambert S. Benita 2004 Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors Pharm. Res. 21 261 270
20. B. Heurtault, P. Saulnier, J. P. Benoit, J. E. Proust, B. Pech, and J. Richard. Nanocapsules comprising (semi-) liquid lipid core and solid lipid shell, prepared by phase inversion methods, useful for administration of lipophilic or hydrophilic drugs by injection, orally or intranasally, 2000. Patent WO 01/64328.
21. B. Heurtault P. Saulnier B. Pech J. E. Proust J. P. Benoit 2002 A novel phase inversion-based process for the preparation of lipid nanocarriers Pharm. Res. 19 875 880
22. J. S. Coon W. Knudson K. Clodfelter B. Lu R. S. Weinstein 1991 Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance Cancer Res. 51 897 902
23. J. P. Benoit and A. Lamprecht. Use of P-glycoprotein inhibitor surfactants at the surface of a colloidal carrier, 2004. Patent WO2004071498.
24. K. H. Diehl R. Hull D. Morton R. Pfister Y. Rabemampianina D. Smith J. M. Vidal C. van de Vorstenbosch 2001 A good practice guide to the administration of substances and removal of blood, including routes and volumes J. Appl. Toxicol. 21 15 23
25. A. Lamprecht Y. Bouligand J. P. Benoit 2002 New lipid nanocapsules exhibit sustained release properties for amiodarone J. Control. Release 84 59 68
26. M. Pereira de Oliveira, E. Garcion, N. Venisse, J. P. Benoit, W. Couet, and J. C. Olivier. Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice. Pharm. Res. 22:1898-1905 (2005).
27. C. Dulieu D. Bazile 2005 Influence of lipid nanocapsules composition on their aptness to freeze-drying Pharm. Res. 22 285 292
28. J. S. Choi B. W. Jo Y. C. Kim 2004 Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin Eur. J. Pharm. Biopharm. 57 313 318
29. J. D. Adams, K. P. Flora, B. R. Goldspiel, J. W. Wilson, S. G. Arbuck, and R. Finley. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J. Natl. Cancer Inst. Monogr. 15:141-147 (1993).
30. K. S. Lown R. R. Mayo A. B. Leichtman H. L. Hsiao D. K. Turgeon P. Schmiedlin-Ren M. B. Brown W. Guo S. J. Rossi L. Z. Benet P. B. Watkins 1997 Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine Clin. Pharmacol. Ther. 62 248 260
31. B. Monsarrat, P. Alvinerie, M. Wright, J. Dubois, F. Gueritte-Voegelein, D. Guenard, R. C. Donehower, and E. K. Rowinsky. Hepatic metabolism and biliary excretion of Taxol in rats and humans. J. Natl. Cancer Inst. Monogr. 15:39-46 (1993).
32. J. M. Meerum Terwogt M. M. Malingre J. H. Beijnen W. W. ten Bokkel Huinink H. Rosing F. J. Koopman O. van Tellingen M. Swart J. H. Schellens 1999 Coadministration of oral cyclosporin A enables oral therapy with paclitaxel Clin. Cancer Res. 5 3379 3384
33. L. E. Buckingham M. Balasubramanian R. M. Emanuele K. E. Clodfelter J. S. Coon 1995 Comparison of solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents Int. J. Cancer 62 436 442
34. W. N. Charman 2000 Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts J. Pharm. Sci. 89 967 978
35. S. M. Caliph W. N. Charman C. J. Porter 2000 Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats J. Pharm. Sci. 89 1073 1084
36. Y. Jiao N. Ubrich M. Marchand-Arvier C. Vigneron M. Hoffman T. Lecompte P. Maincent 2002 In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits Circulation 105 230 235
37. M. Aprahamian C. Michel W. Humbert J. P. Devissaguet C. Damge 1987 Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine Biol. Cell 61 69 76
38. M. M. Malingre J. H. Beijnen H. Rosing F. J. Koopman O. van Tellingen K. Duchin W. W. Ten Bokkel Huinink M. Swart J. Lieverst J. H. Schellens 2001 A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A Cancer Chemother. Pharmacol. 47 347 354